Skip to main content

Technivie FDA Approval History

FDA Approved: Yes (Discontinued) (First approved July 24, 2015)
Brand name: Technivie
Generic name: ombitasvir, paritaprevir and ritonavir
Dosage form: Tablets
Company: AbbVie Inc.
Treatment for: Hepatitis C

Marketing Status: Discontinued

Technivie (ombitasvir, paritaprevir and ritonavir) is an NS5A inhibitor, NS3/4A protease inhibitor, and CYP3A inhibitor fixed-dose combination indicated for use in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection.

In May 2018, the FDA announced that Technivie was to be discontinued. The discontinuation was voluntary and not related to the safety, quality, or efficacy of the medicine. It was estimated that Technivie would be available until January 1, 2019.

Development timeline for Technivie

Jul 24, 2015Approval FDA Approves Technivie (ombitasvir, paritaprevir and ritonavir) for Chronic Hepatitis C Genotype 4 Infections

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.